

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 20, 2025

DU145

RRID:CVCL_0105

Type: Cell Line

Proper Citation

(RRID:CVCL_0105)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0105

Proper Citation: (RRID:CVCL_0105)

Sex: Male

Defining Citation: [PMID:631930](#), [PMID:1574572](#), [PMID:1873816](#), [PMID:2744886](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6244232](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:8104329](#), [PMID:8510267](#), [PMID:9018337](#), [PMID:9214606](#), [PMID:9460501](#), [PMID:10700174](#), [PMID:10702678](#), [PMID:10972993](#), [PMID:11135431](#), [PMID:11172901](#), [PMID:11280753](#), [PMID:11304728](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:12606952](#), [PMID:12615715](#), [PMID:12725112](#), [PMID:14518029](#), [PMID:15486987](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:17254797](#), [PMID:17440963](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22275356](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23671654](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:23957452](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:30244336](#), [PMID:30629668](#), [PMID:30787054](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38892296](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line

Encyclopedia - CCLE).

Category: Cancer cell line

Name: DU145

Synonyms: DU-145, Du-145, DU 145, DU_145, DU.145, Duke University 145

Cross References: BTO:BTO_0001332, CLO:CLO_0002840, CLO:CLO_0051536, EFO:EFO_0005441, MCCL:MCC:0000140, CLDB:cl1108, CLDB:cl1109, CLDB:cl4961, CLDB:cl5184, AddexBio:C0019004/4984, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-81, BCRC:60348, BCRJ:0078, BioGRID_ORCS_Cell_line:860, BioSample:SAMN03472017, BioSample:SAMN03472041, BioSample:SAMN03472757, BioSample:SAMN05292468, BioSample:SAMN10988253, cancercellines:CVCL_0105, CCRID:1101HUM-PUMC000006, CCRID:3101HUMSCSP5024, CCRID:3101HUMTCHu222, Cell_Model_Passport:SIDM00120, ChEMBL-Cells:ChEMBL3308034, ChEMBL-Targets:ChEMBL613508, CLS:300168, Cosmic:688116, Cosmic:699306, Cosmic:704850, Cosmic:721367, Cosmic:721558, Cosmic:755299, Cosmic:759893, Cosmic:801349, Cosmic:809223, Cosmic:809224, Cosmic:850415, Cosmic:850824, Cosmic:869156, Cosmic:875891, Cosmic:876395, Cosmic:897454, Cosmic:905935, Cosmic:911998, Cosmic:918501, Cosmic:921050, Cosmic:922550, Cosmic:923401, Cosmic:923956, Cosmic:943177, Cosmic:948075, Cosmic:949247, Cosmic:974300, Cosmic:1028649, Cosmic:1028700, Cosmic:1057758, Cosmic:1070887, Cosmic:1071478, Cosmic:1071905, Cosmic:1075274, Cosmic:1092597, Cosmic:1172627, Cosmic:1175887, Cosmic:1176617, Cosmic:1212490, Cosmic:1218869, Cosmic:1305381, Cosmic:1312368, Cosmic:1330912, Cosmic:1436047, Cosmic:1481419, Cosmic:1542078, Cosmic:1689715, Cosmic:1712065, Cosmic:1995389, Cosmic:1998439, Cosmic:2580127, Cosmic:2585152, Cosmic:2585229, Cosmic:2592487, Cosmic:2651768, Cosmic:2669167, Cosmic:2674179, Cosmic:2816220, Cosmic-CLP:905935, DepMap:ACH-000979, DSMZ:ACC-261, DSMZCellDive:ACC-261, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS077VSE, ENCODE:ENCBS721QHV, GDSC:905935, GEO:GSM2120, GEO:GSM50224, GEO:GSM50288, GEO:GSM91924, GEO:GSM142455, GEO:GSM142456, GEO:GSM482671, GEO:GSM525794, GEO:GSM648818, GEO:GSM648819, GEO:GSM743479, GEO:GSM750774, GEO:GSM750834, GEO:GSM784791, GEO:GSM799369, GEO:GSM799379, GEO:GSM799432, GEO:GSM799442, GEO:GSM843494, GEO:GSM886988, GEO:GSM888057, GEO:GSM1153440, GEO:GSM1153441, GEO:GSM1181273, GEO:GSM1181302, GEO:GSM1181306, GEO:GSM1181328, GEO:GSM1374469, GEO:GSM1374470, GEO:GSM1669745, GEO:GSM2124639, IARC_TP53:751, ICLC:HTL99013, IZSLER:BS TCL 141, KCB:KCB 200701YJ, KCLB:30081, LiGeA:CCLE_356, LINCX_LDP:LCL-1146, Lonza:761, NCBI_Iran:C428, NCI-DTP:DU-145, PharmacDB:DU145_309_2019, PRIDE:PXD003105, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0105, PubChem_Cell_line:CVCL_0105, RCB:RCB2143, SKY/M-FISH/CGH:2792, TKG:TKG 0604, TOKU-E:1103, Wikidata:Q5206280

ID: CVCL_0105

Record Creation Time: 20220427T215824+0000

Record Last Update: 20250420T105930+0000

Ratings and Alerts

No rating or validation information has been found for DU145.

No alerts have been found for DU145.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4292 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Gulliver C, et al. (2024) cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression. *Molecular oncology*, 18(3), 707.

Sugawara T, et al. (2024) Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. *Molecular oncology*, 18(3), 726.

Ibáñez-Molero S, et al. (2024) Phosphoprotein dynamics of interacting T cells and tumor cells by HySic. *Cell reports*, 43(1), 113598.

He J, et al. (2024) PTEN-mediated dephosphorylation of 53BP1 confers cellular resistance to DNA damage in cancer cells. *Molecular oncology*, 18(3), 580.

Liu S, et al. (2024) Protocol for establishing spontaneous metastasis in mice using a subcutaneous tumor model. *STAR protocols*, 5(3), 103239.

Sen A, et al. (2024) Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. *Molecular oncology*.

Lee KY, et al. (2024) Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3. *Journal of Cancer*, 15(3), 615.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. *iScience*, 27(3), 108794.

Boulton DP, et al. (2024) MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity. *Cell reports*, 44(1), 115120.

Liu X, et al. (2024) USP7 reduces the level of nuclear DICER, impairing DNA damage response and promoting cancer progression. *Molecular oncology*, 18(1), 170.

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. *Cell reports. Medicine*, 5(2), 101388.

Ruiz de Porras V, et al. (2024) Dual inhibition of MEK and PI3K α -a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer. *Frontiers in pharmacology*, 15, 1331648.

Beatson EL, et al. (2024) Genomic Characterization of Preclinical Prostate Cancer Cell Line Models. *International journal of molecular sciences*, 25(11).

Ippolito L, et al. (2024) Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer. *EMBO reports*, 25(8), 3506.

Schofield JH, et al. (2024) Acod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides. *Cell reports*, 43(4), 113984.

Salloom RJ, et al. (2024) Targeting heme degradation pathway augments prostate cancer cell sensitivity to docetaxel-induced apoptosis and attenuates migration. *Frontiers in oncology*, 14, 1431362.

Yuan H, et al. (2024) Acetylated KHSRP impairs DNA-damage-response-related mRNA decay and facilitates prostate cancer tumorigenesis. *Molecular oncology*.

Haas R, et al. (2024) The Proteogenomics of Prostate Cancer Radioresistance. *Cancer research communications*, 4(9), 2463.

Luo Y, et al. (2024) Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance. *International journal of cancer*, 155(4), 742.